<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02315638</url>
  </required_header>
  <id_info>
    <org_study_id>B2801002</org_study_id>
    <nct_id>NCT02315638</nct_id>
  </id_info>
  <brief_title>Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.</brief_title>
  <official_title>Follow-up to Study Protocol B2801001, A Phase I/II, Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 in Patients With Chronic Hepatitis C [CHC] Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tacere Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tacere Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term safety follow-up protocol for subjects who received TT-034 under the
      B2801001 protocol and consists of monitoring for at least 4.5 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this follow-up study is to detect events suggestive of delayed adverse
      effects of the study drug by review of clinical histories and discussion with subjects to
      identify/elicit significant medical events, including but not limited to hematologic,
      malignant, autoimmune, neurologic, and hepatic events.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long Term Safety as measured through an assessment of adverse events</measure>
    <time_frame>4.5 years</time_frame>
    <description>The primary objective is to assess the long-term safety of TT-034 administered in subjects with CHC through an assessment of adverse events with a focus on hematologic, malignant, autoimmune, neurologic and hepatic events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long Term Viral Load</measure>
    <time_frame>4.5 years</time_frame>
    <description>The secondary objective is to monitor long-term HCV viral load, as available, of subjects who have received TT-034.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">9</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Dosed subjects</arm_group_label>
    <description>There is no intervention. This is a observational study monitoring subjects that were dosed with TT-034 in the Tacere B2801001 study,</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be collected and archived for further testing, should future data suggest
      that it is clinically or scientifically indicated.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is comprised of subjects that were enrolled in Study B2801001 and who
        received a dose of TT-034.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior enrollment in Study B2801001 and dosing with TT-034

          -  An informed consent form for this study signed and dated by the subject or a legally
             acceptable representative

        Exclusion Criteria:

          -  There are no specific exclusion criteria for this follow-up study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Suhy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tacere Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Clinical Research Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2014</study_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adeno-associated viral vectors</keyword>
  <keyword>Adeno-associated virus</keyword>
  <keyword>AAV</keyword>
  <keyword>AAV8</keyword>
  <keyword>ddRNAi</keyword>
  <keyword>shRNA</keyword>
  <keyword>RNAi</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>CHC</keyword>
  <keyword>Genotype 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

